"Recurrence" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The return of a sign, symptom, or disease after a remission.
Descriptor ID |
D012008
|
MeSH Number(s) |
C23.550.291.937
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recurrence".
Below are MeSH descriptors whose meaning is more specific than "Recurrence".
This graph shows the total number of publications written about "Recurrence" by people in this website by year, and whether "Recurrence" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 36 | 36 |
1995 | 0 | 35 | 35 |
1996 | 0 | 28 | 28 |
1997 | 0 | 35 | 35 |
1998 | 0 | 39 | 39 |
1999 | 0 | 40 | 40 |
2000 | 0 | 40 | 40 |
2001 | 0 | 30 | 30 |
2002 | 0 | 29 | 29 |
2003 | 0 | 58 | 58 |
2004 | 2 | 61 | 63 |
2005 | 0 | 52 | 52 |
2006 | 0 | 69 | 69 |
2007 | 0 | 61 | 61 |
2008 | 0 | 77 | 77 |
2009 | 1 | 67 | 68 |
2010 | 0 | 85 | 85 |
2011 | 0 | 114 | 114 |
2012 | 0 | 101 | 101 |
2013 | 0 | 96 | 96 |
2014 | 0 | 84 | 84 |
2015 | 0 | 82 | 82 |
2016 | 0 | 72 | 72 |
2017 | 0 | 93 | 93 |
2018 | 0 | 100 | 100 |
2019 | 0 | 92 | 92 |
2020 | 0 | 81 | 81 |
2021 | 0 | 74 | 74 |
2022 | 0 | 53 | 53 |
2023 | 0 | 60 | 60 |
2024 | 0 | 9 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recurrence" by people in Profiles.
-
Identification of Colorectal Cancer Cell Stemness from Single-Cell RNA Sequencing. Mol Cancer Res. 2024 Apr 02; 22(4):337-346.
-
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood. 2024 Mar 28; 143(13):1269-1281.
-
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. Oncology (Williston Park). 2024 03 01; 38(3):104-106.
-
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. Cancer Cell. 2024 Mar 11; 42(3):444-463.e10.
-
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 May; 99(5):836-843.
-
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 Apr; 38(4):720-728.
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.
-
Adoptive cellular therapy after hematopoietic stem cell transplantation. Am J Hematol. 2024 May; 99(5):910-921.
-
Management of aggressive lymphoma after CAR T-cell therapy failure. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):364-369.